Latest Headlines

  1. Patented Device Reinvents Solid Phase Extraction 8/25/2026

    Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition. Small enough to fit in your lab coat pocket, yet so powerful it will accomplish complete SPE procedures within minutes.

  2. Ataraxis AI's Laboratory Receives CAP Accreditation And California Clinical Laboratory License 8/25/2026

    Ataraxis AI, a frontier clinical artificial intelligence (AI) company developing AI-powered tools for oncology, today announced that its laboratory has received accreditation from the College of American Pathologists (CAP) and a clinical laboratory license from the State of California, expanding access to the Ataraxis Breast platform for clinicians and patients across the state.

  3. Thermo Fisher Scientific Launches First Orbitrap Mass Spectrometers For Isotope Ratio Analysis, Enabling More Labs To Decode The Story Behind A Sample 8/25/2026

    Thermo Fisher Scientific, the world leader in serving science, today introduced the Thermo Scientific Orbitrap Isora Mass Spectrometer and Orbitrap Isora Pro Mass Spectrometer, the company’s first Orbitrap instruments with a dedicated isotope ratio analysis mode.

  4. Labcorp To Offer First FDA-Cleared Blood Test To Detect Alzheimer's Disease Pathology In Both Primary And Specialty Care Settings 8/24/2026

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA).

  5. Quest Diagnostics To Offer FDA-Cleared Roche pTau217 Blood Test To Assess Alzheimer's Disease Pathology 8/24/2026

    Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced two new developments for its Quest AD-Detect® portfolio of blood-based biomarker tests for Alzheimer's disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer's disease.

  6. Purdue Innovation Enhances Multiomics Workflow, Eliminates Sample Preparation 8/24/2026

    A patent-pending method developed and tested for multiple applications at Purdue University eliminates sample preparation, a bottleneck that currently dominates a laboratory scientist’s time and budget, and is amenable with spatial analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

  7. Seek Labs And NAMRU EURAFCENT Enter CRADA To Evaluate Field-Deployable Diagnostics For Infectious Diseases 8/24/2026

    Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, today announced a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Unit (NAMRU) EURAFCENT, part of Navy Medicine Research & Development that is focused on infectious disease threats affecting military personnel, to evaluate SeekIt™, the company’s instrument-free molecular diagnostic platform. 

  8. Rznomics Joins Lilly Gateway Labs In San Diego To Accelerate RNA Therapeutics 8/23/2026

    Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California.

  9. FDA Clears C2N Diagnostics' PrecivityAD2 — First Alzheimer's Blood Test For Adults With Cognitive Symptoms As Young As 40 8/20/2026

    The U.S. Food & Drug Administration (FDA) has cleared C2N Diagnostics’ PrecivityAD2 test, providing patients and health care professionals with an accurate, accessible, and scalable blood test to help diagnose Alzheimer’s disease in conjunction with standard clinical workup.

  10. Pillar Biosciences, LC-SCRUM-Asia And LSI Medience Announce Liquid Biopsy Screening Collaboration In Lung Cancer 8/19/2026

    Pillar Biosciences, Inc. (“Pillar”), LC-SCRUM-Asia and LSI Medience Corporation (“LSI Medience”) today announced a collaboration to support genomic screening of blood-based samples from patients with lung cancer as part of the LC-SCRUM-Asia project in Japan.